TRAIL对肿瘤侵润CD4^+CD25^+Treg的调节作用  

Regulation of TRAIL on tumor infiltrating CD4^+CD25^+Treg

作　　者：袁海芹[1] 刁智娟[1] 周剑锁[1] 刘彦信[1] 史娟[1] 郑德先[1] 

机构地区：[1]中国医学科学院基础医学研究所北京协和医学院基础学院,北京100005

出　　处：《中国免疫学杂志》2011年第6期507-510,共4页Chinese Journal of Immunology

基　　金：国家自然基金面上项目(30772495;30972699)

摘　　要：目的:探讨TRAIL对肿瘤侵润CD4+CD25+Treg细胞的调节作用。方法:ELISA检测TRAIL对肿瘤细胞分泌CCL22的影响;建立对TRAIL耐受的4T1肿瘤细胞皮下实体瘤模型,瘤内给予重组TRAIL蛋白,检测肿瘤体积的变化;分离肿瘤侵润的淋巴细胞,采用流式细胞术检测瘤内CD4+CD25+Treg细胞的变化。结果:TRAIL引起肿瘤细胞4T1和B16培养上清中CCL22水平增加;TRAIL治疗组与对照组相比,对TRAIL耐受的4T1移植瘤体积没有明显变化,但TRAIL治疗组的肿瘤侵润CD4+CD25+Treg细胞显著增加。结论:TRAIL引起肿瘤细胞分泌CCL22,可因此诱导CD4+CD25+Treg细胞趋化至肿瘤部位导致肿瘤侵润的CD4+CD25+Treg比例增加,为TRAIL的生理功能和在肿瘤治疗中的应用提供了新的资料。Objective： To investigate the regulation of TRAIL on tumor infiltrating CD4^＋ CD25^＋ Treg cells. Methods： The impact of TRAIL on CCL22 secretion of tumor cells was detected by ELISA. Recombinant soluble TRAIL was administrated into subcutaneous solid 4T1 tumor and tumor volume was measured. Tumor infiltrating lymphocytes were isolated and assayed by flow cytometry to evaluate the change of CD4^＋CD25^＋ Treg cells in tumor. Results： rsTRAIL increased CCL22 secretion into supernatant of tumor cell 4T1 and B16 cells. TRAIL treatment did not inhibit the s. c. 4T1 tumor gYowth, but tumor infihrating CD4^＋ CD25^＋ Treg increased obviously. Conclusion： Augmention in CCI22 secretion of 4T1 cancer cells might recruit Tregs, therefore, leading to tumor infiltrating CD4^＋CD25^＋Treg increase. This study provides novel data for the physiological function research of TRAIL and cancer therapy application.

关 键 词：肿瘤坏死因子相关凋亡诱导配体 趋化因子(c-c模型)配体22 CD4+CD25+调节型T细胞 

分 类 号：R392.11[医药卫生—免疫学]